{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T21:47:33Z","timestamp":1775166453289,"version":"3.50.1"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica NV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen Vaccines & Prevention B.V."},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Current serologic tests for HIV screening and confirmation of infection present challenges to the adoption of HIV vaccines. The detection of vaccine-induced HIV-1 antibodies in the absence of HIV-1 infection, referred to as vaccine-induced seropositivity\/seroreactivity, confounds the interpretation of test results, causing misclassification of HIV-1 status with potential affiliated stigmatization. For HIV vaccines to be widely adopted with high community confidence and uptake, tests are needed that are agnostic to the vaccination status of tested individuals (ie, positive only for true HIV-1 infection). Successful development and deployment of such tests will require HIV vaccine developers to work in concert with diagnostic developers. Such tests will need to match today's high-performance standards (accuracy, cost-effectiveness, simplicity) for use in vaccinated and unvaccinated populations, especially in low- and middle-income countries with high HIV burden. Herein, we discuss the challenges and strategies for developing modified serologic HIV tests for concurrent deployment with HIV vaccines.<\/jats:p>","DOI":"10.1093\/infdis\/jiae113","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T17:47:34Z","timestamp":1709833654000},"page":"1919-1925","source":"Crossref","is-referenced-by-count":6,"title":["HIV Diagnostics and Vaccines: It Takes Two to Tango"],"prefix":"10.1093","volume":"229","author":[{"given":"Will","family":"Col\u00f3n","sequence":"first","affiliation":[{"name":"Johnson & Johnson Global Public Health Research and Development , Beerse ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4734-1729","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Oriol-Mathieu","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention B.V. , Leiden ,","place":["the Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Hural","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Hattingh","sequence":"additional","affiliation":[{"name":"LH Consulting , Berkeley, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0873-7993","authenticated-orcid":false,"given":"Ferdinard","family":"Adungo","sequence":"additional","affiliation":[{"name":"Kenya Medical Research Institute , Nairobi ,","place":["Kenya"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole","family":"Lagatie","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Global Public Health Research and Development , Beerse ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludo","family":"Lavreys","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention B.V. , Leiden ,","place":["the Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Allen","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omu","family":"Anzala","sequence":"additional","affiliation":[{"name":"Kenya Aids Vaccine Initiative Institute of Clinical Research, University of Nairobi ,","place":["Kenya"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Espy","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrien","family":"Fransen","sequence":"additional","affiliation":[{"name":"HIV\/STD Reference Laboratory, Clinical Virology Unit, Department of Clinical Sciences, Institute of Tropical Medicine , Antwerp ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia J","family":"Garcia","sequence":"additional","affiliation":[{"name":"Epidemiology, STD, and HIV Unit, School of Public Health, Universidad Peruana Cayetano Heredia , Lima ,","place":["Peru"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Milton","family":"Maciel","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurine","family":"Murtagh","sequence":"additional","affiliation":[{"name":"The Murtagh Group, LLC , Woodside, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila A","family":"Peel","sequence":"additional","affiliation":[{"name":"Diagnostics and Countermeasures Branch, Walter Reed Army Institute of Research , Silver Spring, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna W","family":"Peeling","sequence":"additional","affiliation":[{"name":"Clinical Research Department, London School of Hygiene and Tropical Medicine , London ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Litjen L J","family":"Tan","sequence":"additional","affiliation":[{"name":"Immunize.org , Saint Paul, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Warren","sequence":"additional","affiliation":[{"name":"AVAC , New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Grazia","family":"Pau","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention B.V. , Leiden ,","place":["the Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia M","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"2024102112474504500_jiae113-B1","author":"UNAIDS"},{"key":"2024102112474504500_jiae113-B2","doi-asserted-by":"crossref","first-page":"101470","DOI":"10.1016\/j.smim.2021.101470","article-title":"HIV vaccinology: 2021 update","volume":"51","author":"Lee","year":"2021","journal-title":"Semin Immunol"},{"key":"2024102112474504500_jiae113-B3","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2019.1343","article-title":"Ending the HIV epidemic: a plan for the United States","volume":"321","author":"Fauci","year":"2019","journal-title":"JAMA"},{"key":"2024102112474504500_jiae113-B4","author":"UNAIDS"},{"key":"2024102112474504500_jiae113-B5","author":"World Health Organization"},{"key":"2024102112474504500_jiae113-B6","author":"HIV.gov. US statistics"},{"key":"2024102112474504500_jiae113-B7","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.vaccine.2014.10.040","article-title":"HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians","volume":"33","author":"VISR Working Group of Global HIV Vaccine Enterprise","year":"2015","journal-title":"Vaccine"},{"key":"2024102112474504500_jiae113-B8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14760584.2020.1718497","article-title":"Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges","volume":"19","author":"Pitisuttithum","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"2024102112474504500_jiae113-B9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.926","article-title":"Vaccine-induced HIV seropositivity\/reactivity in noninfected HIV vaccine recipients","volume":"304","author":"Cooper","year":"2010","journal-title":"JAMA"},{"key":"2024102112474504500_jiae113-B10","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1097\/QAD.0000000000002310","article-title":"Long-term safety and vaccine-induced seropositivity in healthy volunteers from HIV vaccine trials","volume":"33","author":"Durier","year":"2019","journal-title":"AIDS"},{"key":"2024102112474504500_jiae113-B11","doi-asserted-by":"crossref","first-page":"e0002037","DOI":"10.1371\/journal.pgph.0002037","article-title":"Cross-protocol assessment of induction and durability of VISP\/R in HIV preventive vaccine trial participants","volume":"3","author":"Espy","year":"2023","journal-title":"PLOS Glob Public Health"},{"key":"2024102112474504500_jiae113-B12","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/QAI.0000000000001814","article-title":"Being \u201cfalse positive\u201d: an \u201cinconvenience\u201d? debates and questions regarding the notion of vaccine-induced seropositivity (VISP) in the recruitment of healthy volunteers for a preventive anti-HIV vaccine trial","volume":"79","author":"Couderc","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024102112474504500_jiae113-B13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7196\/SAMJ.2023.v113i1.16670","article-title":"Exploring a community's understanding of HIV vaccine\u2013induced seropositivity in a South African research setting","volume":"113","author":"Malahleha","year":"2022","journal-title":"S Afr Med J"},{"key":"2024102112474504500_jiae113-B14","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1016\/S2666-5247(22)00038-6","article-title":"Diagnostics to make immunisation programmes more efficient, equitable, and effective","volume":"3","author":"Hampton","year":"2022","journal-title":"Lancet Microbe"},{"key":"2024102112474504500_jiae113-B15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coi.2016.05.011","article-title":"New concepts in HIV-1 vaccine development","volume":"41","author":"Stephenson","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"2024102112474504500_jiae113-B16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41577-022-00753-w","article-title":"Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies","volume":"23","author":"Haynes","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"2024102112474504500_jiae113-B17","author":"Janssen Pharmaceuticals"},{"key":"2024102112474504500_jiae113-B18","doi-asserted-by":"crossref","first-page":"eadd6502","DOI":"10.1126\/science.add6502","article-title":"Vaccination induces HIV broadly neutralizing antibody precursors in humans","volume":"378","author":"Leggat","year":"2022","journal-title":"Science"},{"key":"2024102112474504500_jiae113-B19","author":"IAVI"},{"key":"2024102112474504500_jiae113-B20","author":"IAVI"},{"key":"2024102112474504500_jiae113-B21","author":"National Institutes of Health"},{"key":"2024102112474504500_jiae113-B22","author":"World Health Organization"},{"key":"2024102112474504500_jiae113-B23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1128\/CVI.00053-16","article-title":"Human immunodeficiency virus diagnostic testing: 30 years of evolution","volume":"23","author":"Alexander","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"2024102112474504500_jiae113-B24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21106\/ijma.423","article-title":"Utilization of rapid diagnostic testing in sub-Saharan Africa: challenges and effects on HIV prevention","volume":"10","author":"Armstrong-Mensah","year":"2021","journal-title":"Int J MCH AIDS"},{"key":"2024102112474504500_jiae113-B25","doi-asserted-by":"crossref","first-page":"e02045-17","DOI":"10.1128\/JCM.02045-17","article-title":"Comparison of detection limits of fourth- and fifth-generation combination HIV antigen-antibody, p24 antigen, and viral load assays on diverse HIV isolates","volume":"56","author":"Stone","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2024102112474504500_jiae113-B26","author":"Centers for Disease Control and Prevention"},{"key":"2024102112474504500_jiae113-B27","author":"World Health Organization"},{"key":"2024102112474504500_jiae113-B28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/cid\/ciw666","article-title":"Time until emergence of HIV test reactivity following infection with HIV-1: implications for interpreting test results and retesting after exposure","volume":"64","author":"Delaney","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024102112474504500_jiae113-B29","author":"World Health Organization"},{"key":"2024102112474504500_jiae113-B30","author":"European Commission"},{"key":"2024102112474504500_jiae113-B31","author":"European Centre for Disease Prevention and Control"},{"key":"2024102112474504500_jiae113-B32","author":"Centers for Disease Control and Prevention, Association of Public Health Laboratories"},{"key":"2024102112474504500_jiae113-B33","author":"Centers for Disease Control and Prevention"},{"key":"2024102112474504500_jiae113-B34","author":"University of Queensland"},{"key":"2024102112474504500_jiae113-B35","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S1473-3099(21)00200-0","article-title":"Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"21","author":"Chappell","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024102112474504500_jiae113-B36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41564-018-0295-3","article-title":"REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes","volume":"4","author":"Land","year":"2019","journal-title":"Nat Microbiol"},{"key":"2024102112474504500_jiae113-B37","doi-asserted-by":"crossref","first-page":"e004418","DOI":"10.1136\/bmjgh-2020-004418","article-title":"HIV self-testing: lessons learnt and priorities for adaptation in a shifting landscape","volume":"6","author":"Gupta-Wright","year":"2021","journal-title":"BMJ Glob Health"},{"key":"2024102112474504500_jiae113-B38","author":"World Health Organization"},{"key":"2024102112474504500_jiae113-B39","doi-asserted-by":"crossref","first-page":"e0071523","DOI":"10.1128\/spectrum.00715-23","article-title":"Towards novel HIV-1 serodiagnostic tests without vaccine-induced seroreactivity","volume":"11","author":"Lagatie","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2024102112474504500_jiae113-B40","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/CVI.00748-13","article-title":"Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants","volume":"21","author":"Penezina","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"2024102112474504500_jiae113-B41","author":"National Institutes of Health and Centers for Disease Control and Prevention"},{"key":"2024102112474504500_jiae113-B42","author":"National Institutes of Health"},{"key":"2024102112474504500_jiae113-B43","doi-asserted-by":"crossref","first-page":"05027","DOI":"10.7189\/jogh.11.05027","article-title":"A rapid review of evidence on the determinants of and strategies for COVID-19 vaccine acceptance in low- and middle-income countries","volume":"11","author":"Moola","year":"2021","journal-title":"J Glob Health"},{"key":"2024102112474504500_jiae113-B44","doi-asserted-by":"crossref","first-page":"602659","DOI":"10.3389\/fbioe.2020.602659","article-title":"Microfluidic point-of-care testing: commercial landscape and future directions","volume":"8","author":"Sachdeva","year":"2021","journal-title":"Front Bioeng Biotechnol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae113\/57131160\/jiae113.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/6\/1919\/59930078\/jiae113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/6\/1919\/59930078\/jiae113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T12:48:05Z","timestamp":1729514885000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/229\/6\/1919\/7623683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3,7]]},"published-print":{"date-parts":[[2024,6,14]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae113","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,15]]},"published":{"date-parts":[[2024,3,7]]}}}